Citigroup
ORKA

Citigroup’s Oruka Therapeutics ORKA Stock Holding History

Citigroup’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509K Buy
10,387
+559
+6% +$19.4K ﹤0.01% 3529
2025
Q4 		$298K Buy
9,828
+6,457
+192% +$180K ﹤0.01% 3819
2025
Q3 		$64.8K Sell
3,371
-6,469
-66% -$95.9K ﹤0.01% 4410
2025
Q2 		$110K Buy
9,840
+8,286
+533% +$86.4K ﹤0.01% 4356
2025
Q1 		$15.9K Sell
1,554
-6,474
-81% -$80.7K ﹤0.01% 5125
2024
Q4 		$156K Sell
8,028
-18,692
-70% -$456K ﹤0.01% 4575
2024
Q3 		$655K Buy
+26,720
New +$930K ﹤0.01% 3558
2022
Q2 		– Sell
-149
Closed -$4K – 6743
2022
Q1 		$4K Buy
+149
New +$3.69K ﹤0.01% 5918
2016
Q2 		– Hold
0
– – – 7486
2016
Q1 		– Sell
-1
Closed -$814 – 7808
2015
Q4 		$1K Buy
+1
New +$1.13K ﹤0.01% 7428
2015
Q3 		– Hold
0
– – – 7761
2015
Q1 		– Sell
-1
Closed -$1K – 7475
2014
Q4 		$1K Buy
+1
New +$1.51K ﹤0.01% 7003
2014
Q3 		– Sell
-2
Closed -$4K – 7336
2014
Q2 		$4K Buy
+2
New +$4.65K ﹤0.01% 6558
2013
Q3 		– Sell
-3
Closed -$6K – 7024
2013
Q2 		$6K Buy
+3
New +$9.16K ﹤0.01% 6280

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citigroup's ORKA Position: Q1 2026 in Review

Citigroup increased its Oruka Therapeutics (ORKA) stake by 5.7% in Q1 2026, buying an estimated $19.4K and bringing the position to 10,387 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #3529.

Citigroup first reported a position in ORKA in Q2 2013 and has held it in 12 quarters since. The position peaked at $655K in Q3 2024. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Citigroup held 10,387 shares of Oruka Therapeutics worth $509K as of Q1 2026.
  • Citigroup bought 559 Oruka Therapeutics shares in Q1 2026, an estimated $19.4K.
  • Oruka Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3529 holding.
  • Citigroup first reported a position in Oruka Therapeutics in Q2 2013 and has held it in 12 quarters since.
  • Citigroup's Oruka Therapeutics position peaked at $655K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.